VALBIOTIS Announces Its Participation in the 39th J.P. Morgan Healthcare Annual Conference as well as in H.C. Wainwright BioConnect from January 11-14, 2021, in Virtual Format
VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME) (Paris:ALVAL), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces its participation in the prestigious 'J.P. Morgan Healthcare' annual conference, taking place from 11 to 14 January 2021, in virtual format.
Sébastien Peltier, CEO of VALBIOTIS, and Jocelyn Pineau, CFO, are taking part in this key event for biotechnology and pharmaceutical companies. They will use this opportunity to raise the profile of VALBIOTIS, a company specializing in the prevention of metabolic diseases, with over 10,000 international specialists from the healthcare industry who meet by invitation each year.
Founded in 1983, this annual event has become the most important international conference in the sector. It enables emerging and innovative companies with high growth potential to establish and maintain contacts within the industry and with international investors specialized in the field of health and biotechnologies. VALBIOTIS is one of the French companies invited to this major event.
At the same time, VALBIOTIS is also participating in the H.C. WAINWRIGHT BioConnect 2021 conference. This satellite event dedicated to biotechnologies brings together 350 companies that will be presented to international investors in the sector from January 11 to 14, 2021.
VALBIOTIS will make this most of this opportunity to present its development strategy, as well as the decisive steps already taken in 2020 (including the Partnership with Nestlé Health Science and the launch of the REVERSE-IT study) and the outlook for 2021. This new year looks just as promising, with the launch of the HEART Phase II clinical study for TOTUM-70 (reduction of LDL hypercholesterolemia) initiated in the second half of 2020 and the launch of the Phase II clinical study for TOTUM-854 (reduction of blood pressure).
Download the slideshow of meetings on the Company website, in the Documentation section dedicated to investors: www.valbiotis.com/en/documents/
VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France: Périgny, La Rochelle (17) and Riom (63).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
For more information about VALBIOTIS, please visit: www.valbiotis.com .
ISIN code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-SME 150
This press release contains forward-looking statements about VALBIOTIS' objectives. VALBIOTIS considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). This document is available on the Company's website (www.valbiotis.com ).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MITSUI-MINING-&-SMELTING25.1.2021 07:02:07 CET | Press release
Mitsui Mining & Smelting Co., Ltd. to Initiate Mass Production of HRDP®, a Special Glass Carrier for Next-Generation Semiconductor Packaging Devices
AK-ALASKA-CARGO25.1.2021 06:03:09 CET | Press release
Alaska Cargo and Cold Storage Launches Major Addition to the Global Cold Chain
MA-TAKEDA-PHARMACEUTICAL25.1.2021 01:02:06 CET | Press release
Takeda Named Global Top Employer for Fourth Consecutive Year
TX-GPD-COMPANIES22.1.2021 14:35:10 CET | Press release
GPD Companies, Inc. to Acquire Distrupol
TX-SCHLUMBERGER22.1.2021 12:52:04 CET | Press release
Schlumberger Announces Fourth-Quarter and Full-Year 2020 Results
CA-ANDERSEN-GLOBAL22.1.2021 11:04:11 CET | Pressemeddelelse
Andersen Global styrker sin afrikanske platform med Kashadah & Co.
JEOL22.1.2021 07:02:12 CET | Press release
JEOL: Release of a New Cold Field Emission Cryo-Electron Microscope CRYO ARM™ 300 II (JEM-3300)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom